PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
10.76%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
11.35%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
31.03%
Positive EPS growth while GNPX is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
31.72%
Positive diluted EPS growth while GNPX is negative. John Neff might view this as a strong relative advantage in controlling dilution.
29.31%
Share count expansion well above GNPX's 1.83%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
29.44%
Diluted share count expanding well above GNPX's 1.87%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
2.31%
OCF growth under 50% of GNPX's 4.63%. Michael Burry might suspect questionable revenue recognition or rising costs.
3.06%
FCF growth similar to GNPX's 3.30%. Walter Schloss would attribute it to parallel capital spending and operational models.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-254578.19%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
64.50%
Positive OCF/share growth while GNPX is negative. John Neff might see a comparative advantage in operational cash viability.
73.57%
Positive 3Y OCF/share CAGR while GNPX is negative. John Neff might see a big short-term edge in operational efficiency.
-9976.84%
Negative 10Y net income/share CAGR while GNPX is at 75.52%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-124.34%
Negative 5Y net income/share CAGR while GNPX is 75.52%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
76.73%
3Y net income/share CAGR similar to GNPX's 75.52%. Walter Schloss would attribute it to shared growth factors or demand patterns.
1493.31%
Equity/share CAGR of 1493.31% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-38.28%
Negative 5Y equity/share growth while GNPX is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-74.77%
Negative 3Y equity/share growth while GNPX is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Positive asset growth while GNPX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
127.26%
Positive BV/share change while GNPX is negative. John Neff sees a clear edge over a competitor losing equity.
-9.95%
We’re deleveraging while GNPX stands at 147.52%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.53%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-21.01%
We cut SG&A while GNPX invests at 92.72%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.